A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

Cynthia X. Ma, Vera Jean Suman, Matthew Philip Goetz, Paul Haluska, Timothy Moynihan, Rita Nanda, Olufunmilayo Olopade, Timothy Pluard, Zhanfang Guo, Helen X. Chen, Charles Erlichman, Matthew J. Ellis, Gini F. Fleming

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). We designed a phase I trial to determine the maximum-tolerated dose (MTD) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies. A 3 + 3 Phase I design was chosen. Temsirolimus and Cixutumumab were administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle. Of the 26 patients enrolled, four did not complete cycle 1 because of disease progression (n = 3) or comorbid condition (n = 1) and were replaced. The MTD was determined from the remaining 22 patients, aged 34-72 (median 48) years. Most patients (86 %) had estrogen receptor positive cancer. The median number of prior chemotherapy regimens for metastatic disease was 3. The MTD was determined to be Cixutumumab 4 mg/kg and temsirolimus 15 mg weekly. Dose-limiting toxicities (DLTs) included mucositis, neutropenia, and thrombocytopenia. Other adverse events included grade 1/2 fatigue, anemia, and hyperglycemia. No objective responses were observed, but four patients experienced stable disease that lasted for at least 4 months. Compared with baseline, there was a significant increase in the serum levels of IGF-1 (p < 0.001) and IGFBP-3 (p = 0.019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing.

Original languageEnglish (US)
Pages (from-to)145-153
Number of pages9
JournalBreast Cancer Research and Treatment
Volume139
Issue number1
DOIs
StatePublished - May 2013

Fingerprint

IGF Type 1 Receptor
Maximum Tolerated Dose
Breast Neoplasms
Antibodies
Insulin-Like Growth Factor Binding Protein 3
Sirolimus
Insulin-Like Growth Factor I
Mucositis
Insulin-Like Growth Factor II
Neutropenia
Serum
Hyperglycemia
Thrombocytopenia
Estrogen Receptors
Fatigue
Disease Progression
Anemia
Neoplasms
Up-Regulation
temsirolimus

Keywords

  • Cixutumumab
  • IGF-1R
  • Metastatic breast cancer
  • mTOR
  • Temsirolimus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. / Ma, Cynthia X.; Suman, Vera Jean; Goetz, Matthew Philip; Haluska, Paul; Moynihan, Timothy; Nanda, Rita; Olopade, Olufunmilayo; Pluard, Timothy; Guo, Zhanfang; Chen, Helen X.; Erlichman, Charles; Ellis, Matthew J.; Fleming, Gini F.

In: Breast Cancer Research and Treatment, Vol. 139, No. 1, 05.2013, p. 145-153.

Research output: Contribution to journalArticle

Ma, CX, Suman, VJ, Goetz, MP, Haluska, P, Moynihan, T, Nanda, R, Olopade, O, Pluard, T, Guo, Z, Chen, HX, Erlichman, C, Ellis, MJ & Fleming, GF 2013, 'A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer', Breast Cancer Research and Treatment, vol. 139, no. 1, pp. 145-153. https://doi.org/10.1007/s10549-013-2528-8
Ma, Cynthia X. ; Suman, Vera Jean ; Goetz, Matthew Philip ; Haluska, Paul ; Moynihan, Timothy ; Nanda, Rita ; Olopade, Olufunmilayo ; Pluard, Timothy ; Guo, Zhanfang ; Chen, Helen X. ; Erlichman, Charles ; Ellis, Matthew J. ; Fleming, Gini F. / A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. In: Breast Cancer Research and Treatment. 2013 ; Vol. 139, No. 1. pp. 145-153.
@article{f9b1f652145f4c93a894f218904984d0,
title = "A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer",
abstract = "The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). We designed a phase I trial to determine the maximum-tolerated dose (MTD) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies. A 3 + 3 Phase I design was chosen. Temsirolimus and Cixutumumab were administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle. Of the 26 patients enrolled, four did not complete cycle 1 because of disease progression (n = 3) or comorbid condition (n = 1) and were replaced. The MTD was determined from the remaining 22 patients, aged 34-72 (median 48) years. Most patients (86 {\%}) had estrogen receptor positive cancer. The median number of prior chemotherapy regimens for metastatic disease was 3. The MTD was determined to be Cixutumumab 4 mg/kg and temsirolimus 15 mg weekly. Dose-limiting toxicities (DLTs) included mucositis, neutropenia, and thrombocytopenia. Other adverse events included grade 1/2 fatigue, anemia, and hyperglycemia. No objective responses were observed, but four patients experienced stable disease that lasted for at least 4 months. Compared with baseline, there was a significant increase in the serum levels of IGF-1 (p < 0.001) and IGFBP-3 (p = 0.019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing.",
keywords = "Cixutumumab, IGF-1R, Metastatic breast cancer, mTOR, Temsirolimus",
author = "Ma, {Cynthia X.} and Suman, {Vera Jean} and Goetz, {Matthew Philip} and Paul Haluska and Timothy Moynihan and Rita Nanda and Olufunmilayo Olopade and Timothy Pluard and Zhanfang Guo and Chen, {Helen X.} and Charles Erlichman and Ellis, {Matthew J.} and Fleming, {Gini F.}",
year = "2013",
month = "5",
doi = "10.1007/s10549-013-2528-8",
language = "English (US)",
volume = "139",
pages = "145--153",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A phase i trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

AU - Ma, Cynthia X.

AU - Suman, Vera Jean

AU - Goetz, Matthew Philip

AU - Haluska, Paul

AU - Moynihan, Timothy

AU - Nanda, Rita

AU - Olopade, Olufunmilayo

AU - Pluard, Timothy

AU - Guo, Zhanfang

AU - Chen, Helen X.

AU - Erlichman, Charles

AU - Ellis, Matthew J.

AU - Fleming, Gini F.

PY - 2013/5

Y1 - 2013/5

N2 - The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). We designed a phase I trial to determine the maximum-tolerated dose (MTD) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies. A 3 + 3 Phase I design was chosen. Temsirolimus and Cixutumumab were administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle. Of the 26 patients enrolled, four did not complete cycle 1 because of disease progression (n = 3) or comorbid condition (n = 1) and were replaced. The MTD was determined from the remaining 22 patients, aged 34-72 (median 48) years. Most patients (86 %) had estrogen receptor positive cancer. The median number of prior chemotherapy regimens for metastatic disease was 3. The MTD was determined to be Cixutumumab 4 mg/kg and temsirolimus 15 mg weekly. Dose-limiting toxicities (DLTs) included mucositis, neutropenia, and thrombocytopenia. Other adverse events included grade 1/2 fatigue, anemia, and hyperglycemia. No objective responses were observed, but four patients experienced stable disease that lasted for at least 4 months. Compared with baseline, there was a significant increase in the serum levels of IGF-1 (p < 0.001) and IGFBP-3 (p = 0.019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing.

AB - The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). We designed a phase I trial to determine the maximum-tolerated dose (MTD) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies. A 3 + 3 Phase I design was chosen. Temsirolimus and Cixutumumab were administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle. Of the 26 patients enrolled, four did not complete cycle 1 because of disease progression (n = 3) or comorbid condition (n = 1) and were replaced. The MTD was determined from the remaining 22 patients, aged 34-72 (median 48) years. Most patients (86 %) had estrogen receptor positive cancer. The median number of prior chemotherapy regimens for metastatic disease was 3. The MTD was determined to be Cixutumumab 4 mg/kg and temsirolimus 15 mg weekly. Dose-limiting toxicities (DLTs) included mucositis, neutropenia, and thrombocytopenia. Other adverse events included grade 1/2 fatigue, anemia, and hyperglycemia. No objective responses were observed, but four patients experienced stable disease that lasted for at least 4 months. Compared with baseline, there was a significant increase in the serum levels of IGF-1 (p < 0.001) and IGFBP-3 (p = 0.019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing.

KW - Cixutumumab

KW - IGF-1R

KW - Metastatic breast cancer

KW - mTOR

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84877584614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877584614&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2528-8

DO - 10.1007/s10549-013-2528-8

M3 - Article

VL - 139

SP - 145

EP - 153

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -